Coming 2027
Early detection leads to better outcomes, fewer emergencies, and a longer, healthier life.
The earlier cardiovascular disease is found, the more can be done to prevent serious problems. Many people experience their first cardiac event without warning, and in some cases, it is fatal⁴. Early detection can include blood pressure screening, cholesterol testing, or more advanced imaging. If indicated based on these evaluations, further interventions can be considered, such as medication. For example, high cholesterol has been shown to be a major risk factor for cardiovascular disease and medications, called statins, are available to reduce these levels; studies have shown that statin therapy can cut the risk of heart attacks and strokes⁵. Preventing just one heart attack or stroke through early detection and treatment can save tens of thousands of dollars in healthcare costs and add years of life⁶.
Early detection of cancer gives you more choices for treatment and a better chance to live a longer, healthier life.
Early detection of dementia empowers patients and families to take action — supporting better outcomes, improved quality of life, and more time to prepare for what’s ahead.
Active Research
The full HALO Cardiovascular Disease Pathway launches in 2027 — but HALO is already contributing to active cardiovascular research today.
Recruiting · NCT06112418
A randomized, multi-center trial comparing the Cleerly Coronary Artery Disease (CAD) Staging System — which visualizes and quantifies coronary atherosclerosis — against traditional risk factor-based care for the primary prevention of cardiovascular events in patients with type 2 diabetes, prediabetes, or metabolic syndrome.
HALO Diagnostics (Indian Wells, CA) is a participating site, with Dr. John F. Feller as site contact. Sponsored by Cleerly, Inc. in collaboration with CPC Clinical Research; estimated enrollment of 7,500 patients nationwide.
Contact the Research Team View TRANSFORM on ClinicalTrials.gov